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The insect baculovirus expression system is a valuable tool for the production of vaccine. Many 
subunit vaccines have been expressed in this system. The first vaccine produced in insect cells for 
animal use is now in the market. In this study, we reviewed recent progress of animal’s vaccine 
production for different expression levels and baculovirus genome stability, characteristic features of 
baculovirus expression vector system (BVES), virus link particles, baculovirus expression in 
mammalian cell and methodology of produce subunit vaccines. This review showed that BVES is a 
fantastic tool for vaccine development and it has wonderful feature for future animal vaccine 
development. 
 





Vaccine development has played a pivotal role in the 
history of medical biology for the treatment of diseases 
like polio, smallpox, diphtheria etc. This has resulted in 
increasing the life expectancy of people in the developing 
world. Some of the infectious diseases like small pox, 
bird flu, plague etc, are a natural outcome of human 
beings coming in contact with infected animals. So, in 
order to prevent outbreak of these diseases, it is 
essential to control them at the source level. Vaccinating 
the animals against the causal agents can be an 
important step in this regard. The best example in this 
regard is the successful development of vaccines against 
smallpox. Scientists are now in the process of creating 
new vaccines with greater potential for protecting humans 
and animals (Lombard et al., 2007). Vaccines should be 
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Abbreviation: BVES, Baculovirus expression vector system. 
clinical signs of disease and produce sterile immunity. 
 Available technologies allow us to design vaccines, 
together with their companion diagnostic tests, which 
make it possible to distinguish between vaccinated and 
infected (Pastoret et al., 2007). 
Several effective vaccines are already available for viral 
infection in the market. Some animal viral infections and 
diseases which are likely to be destroyable in the near 
future, such as African swine fever, the wild boar (Sus 
scrofa) for classical swine fever or the African buffalo 
(Syncerus caffer) for foot and mouth disease may be 
suffering from lack of suitable vaccine (Pastoret et al., 
2007). The use of vaccines in animal production systems 
is also often more environmentally safe and friendly 
because it reduces the use of chemicals. An example is 
the anti-tick vaccine which is based on a cryptic intestinal 
antigen of the parasite (Lombard et al., 2007). 
The baculovirus expression vector system (BEVS) has 
been extensively used since the past 23 years to express 
a large variety of proteins. Several researchers have 
proved that BEVS has the ability to produce significant 
amounts of the desired protein in a cellular environment, 
thereby enabling the correct folding,  targeting  and  post- 




translational modification of the expressed protein 
(Martijan et al., 2007). Baculovirus’s capability to transduce 
a wide variety of mammalian cells leads to the 
emergence of baculovirus as a novel vector for in vivo 
and in vitro gene delivery (Gould, 2004). The first vac-
cines produced in insect cells for animal use are now 
available commercially (Van, 2006). 
This review will focus on past progress of vaccine 
development and possibility to produce vaccine in BEVS 





Subunit vaccines are cell free vaccines, made from 
purified antigenic components of pathogenic micro-
organisms, thus, carrying less risk of adverse reactions 
than whole-cell preparations. However, some factors that 
must be considered in the expression of a subunit 
vaccine are its level of expression, immunogenicity and 
protective efficacy, purification and yield, fidelity to natural 
product, cost and safety. Examples of subunit vaccines 
include the vaccines used to protect against pneumonia 
caused by Streptococcus pneumoniae and against a type 
of meningitis (Nene et al., 1995).  
Molecular biology and genetic engineering has good 
impact on vaccine development by providing the tools 
and techniques to produce a single protein in a nucleus 
system. For example, Spodoptera frugiperda SF21AE 
cells infected with recombinant virus expressed p67 as a 
100-kDa molecule (Nene et al., 1995). Also, Theileria 
parva p67 subunit vaccines were produced in BVES 




Recombinant subunit vaccines 
 
Recombinant subunit vaccines eliminates the risks 
associated with handling a pathogenic organism and the 
risks associated with live or killed products reverting to a 






The conventional strategy of vaccine development re-
quires the identity of the pathogenic microorganism and 
its dissection using biochemical, immunological and mi-
crobiological methods in order to identify the com-
ponents important for immunity (Rappuoli, 2001). This 
method is applicable for pathogens that can be cultured 
under in vitro condition. An exception to this has been the 
hepatitis B vaccine where the pathogen, although, unable 
to grow in vitro, could be recovered in large quantities 







This technology takes advantage of the genome 
sequence of the pathogen. The method was first used to 
identify antigen for a vaccine development against 




BEVS FOR VACCINE PRODUCTION 
 
Insect BEVS has been used as an effective tool to make 
recombinant protein(s). There are many transfer vectors 
for inserting foreign genes into the viral genome (Jones 
and Morikawa, 1996). 
The high levels of expression and proper post-
translational modification were the major advantages in 
this system. The researchers have reported that baculo-
virus have capability to transduce a wide variety of 
mammalian cells both in vivo and in vitro. Also, modified 
AcNPVs (Autographa californica nuclear polyhedrosis 
virus) can express exogenous genes in mammalian cells 
(Carbonell et al., 1985; Volkman and Goldsmith, 1983; 
Boyce and Bucher, 1996). 
Baculovirus has recently also been exploited as a 
vaccine expression/delivery vehicle (Yu-Chen et al., 
2008; Vlak and Keus, 1990; Hou et al., 2003; Li et al., 
2003). The recombinant baculovirus was used as expres-
sion vector for developing a prophylactic vaccine against 
severe acute respiratory syndrome-corona virus (SARS-
CoV) (Bai et al., 2008).The baculovirus AcNPV is widely 
used as a vector for expression of foreign genes in insect 
cells (Hofmann et al., 1995). Monique M. Van Oers 
reported the successful expression of a wide variety of 
viral (glyco) proteins in baculovirus system for vaccine 
purposes (Van, 2006). Also, the successful expression of 
glycoprotein E1 of hog cholera virus in insect cells has 
been utilized to protect swines from hog cholera (Hulst et 
al., 1993). Besides, insect cells are excellent candidates 
for development of new safe and effective HCV subunit 
vaccine. 
The literatures have shown that recombinant hemag-
glutinin subunit vaccines produced through BEVS is a 
more convenient effective and cheaper method for 
broadly targeted protection against avian influenza 





Baculovirus have lot of advantages for research purpose 
with regards to vaccine development. This includes its 
high expression levels, limitless size of expressed 
protein, efficient cleavage of signal peptides, processing 
of the protein and post-translational modifications, 
simultaneous expression of multiple genes and short time 
for   protein   expression  (Patterson et al., 1995;  Luckow  




Table 1. Characteristics of the major protein expression systems. 
 
Characteristic Bacterial Yeast Mammalian Insect 
Proteolytic cleavage May be May be Yes Yes 
Glycosylation No Yes Yes Yes 
Secretion May be Yes Yes Yes 
Folding May be May be Yes Yes 
Phosphorylation No Yes Yes Yes 
Acylation  No Yes Yes Yes 
Amidation No No Yes Yes 
Yield (dry weight) (%) 1-5 1 <1 30 
 




and Summers, 1988; Beljelarskaya, 2002) (Table 1). 
BEVS technology combines the protein authenticity of 
higher eukaryotic systems with the efficiency of microbial 
systems, which is a highly efficient expression vector in 
insect and mammalian cells (Yu-chen, 2005) (Table 1). 
The baculovirus production process can be easily defined 
as a batch process with higher tolerance to osmolality 





Baculovirus is used as a viral vector for gene therapy 
because the production of many viral vectors requires 
either plasmid transfection into producer cell lines or 
helper virus infection (Yu-chen, 2005). The diversity of 
AcNPV-based transfer vectors, combined with available 
S. frugiperda Sf9 and Sf21 cell lines, establish 
baculovirus expression as a preferred system for func-
tional eukaryotic gene expression and the large-scale 
production of recombinant proteins. 
 
 
Adaptations for secreted proteins  
 
Tan et al. has reported that the respiratory syncytial virus 
(RSV) fusion (F) protein was expressed in insect cells as 
recombinant glutathione-S-transferase (GST)-tagged pro-
teins (Tan et al., 2003; Knops et al., 1991). Several 
researchers have reported that IL-18 expressed in BEVS 
is an effective vaccine adjuvant in mice and non-human 
primates (Eberl et al., 2000; Kim et al., 1999). 
 
 
Baculovirus vectors with mammalian cell  
 
Since 1983, baculoviruses have been used to express 
recombinant genes under strong insect-virus promoters 
in insect cells. In 1995, it was discovered that recom-
binant baculoviruses are able to deliver genes into 
mammalian cells. 
The baculovirus vectors as mammalian cell gene 
delivery vectors are constantly increasing and the system 
improvement is going on. We may be concerned that 
baculoviruses are applied in cell-based assays for drug 
screening which requires long period of time to generate 
stable cell lines. Also, baculovirus vector can transfer 
very large DNA in to mammalian cells and vectors for 
toxic gene products can be generated.  
The application of modified baculoviruses for in vivo 
gene delivery has also been demonstrated. The baculo-
viruses have the own property of replicating in insect cells 
while being incapable of initiating a replication cycle and 
producing infectious virus in mammalian cells. Baculo-
viruses are valuable tools for launching viral infection in 
cases where there is no appropriate cell culture system 
available (Kost and Condreay, 2002). Mammalian cells 
incubated with the culture supernatant of infected Sf9 (S. 
frugiperta) cells could serve as a very convenient way for 
rapid and efficient expression of foreign genes in 
mammalian cells, but it might be more suitable for 
primate adherent culture cells (Cheng et al., 2004). 
 
 
VIRAL SUBUNITS EXPRESSION IN THE 
BACULOVIRUS SYSTEM 
 
The nucleocapsid (N) gene of turkey coronavirus (TCV) 
was expressed in baculovirus expression system. The 
experiment had showed that baculovirus-expressed TCV, 
N protein is a suitable source of antigen for ELISA-based 
detection of TCV-specific antibodies in turkeys (Breslin et 
al., 2001).  
In this case, HIV-1 glycoprotein 120 binding to 
recombinant N-methyl-D-aspartate (NMDA) receptor 
subunits is expressed in a baculovirus system. The result 
showed that HIV-1 gp120 could directly bind to the NMDA 
receptor (Xin et al., 1999). Also, virus-specified tubules of 
epizootic haemorrhagic disease virus which are using a 




Viral envelope proteins 
 
The    baculovirus-insect   cell   expression  system  is  an 




advance system for the production of viral antigens with 
vaccine potential for humans and animals. The wide 
variety of viral (glyco) proteins has been successfully 
expressed in this system for vaccine purposes (Van Oers 
and Vlak, 2007). 
Recombinant dengue-2 virus envelope protein has 
been produced in baculovirus infected insect cells 
(Delenda et al., 1994; Zhang et al., 1988). Many 
scientists have shown that expressing vesicular stomatitis 
virus glycol-protein (VSV-G) in the viral envelope was 
generated by inserting the VSV-G coding sequence 
downstream of the polyhedrin promoter (Facciabene et 





Norwalk virus (NV) is a major cause of epidemic 
gastroenteritis. The NV capsid is composed of a single 
protein that forms recombinant (rNV) virus-like particles 
(VLPs) (Ball et al., 1996). Recombinant Norwalk virus-like 
particles (rNV VLPs), produced in insect cells were 
evaluated as a source of oral immunogen in CD1 and 
BALB/c mice by monitoring rNV-specific serum (Ball et 
al., 1998). 
The ability to make a large variety of virus-like particles 
(VLPs) has been successfully achieved in the BEVS/ 
insect cell system (Aucoin et al., 2007). Examples include 
the adeno-associated viral (AAV) particles (Sollerbrant et 
al., 2001), Nudaurelia capensis omega virus (NomegaV) 
(Maree et al., 2006) etc. Influenza virus-like particle (VLP) 
is being tested as a new generation of non-egg or non-
mammalian cell culture-based candidate vaccine against 
influenza infection (Bright et al., 2007). 
 
 
Inclusion of recombinant cytokines in the vaccine 
 
Animal protection studies suggest that synergistic 
combinations of cytokines may be essential to protect the 
body from a viral challenge. In this regard, cytokines used 
in heterologous prime-boost strategies with viral vector 
vaccines or recombinant proteins, might afford the most 
potent vaccine approaches (Ahlers et al., 2003). For 
example, GM-CSF (granulocyte-macrophage colony-
stimulating factor) DNA induces specific patterns of 
cytokines which could provides the basis for development 
of new strategies to develop cancer vaccines, including 
the use of cytokine genes as adjuvant (Perales et al., 
2002; Kämpgen et al., 1994). 
 
 
Baculoviruses as DNA vaccines 
 
Baculoviral vectors with mammalian promoters driving 
the expression of viral genes have been used in a 





injection with baculovirus (BV) expressing the E2 glyco-
protein of hepatitis C virus controlled by the CMV promo-
ter and an enhancer provided specific humoral and 
cellular responses (Facciabene et al., 2004).  
Baculovirus vector with the influenza hemagglutinin 
(H1) controlled by chicken beta actin promotor gave a 
similar level of protection as a wild type baculovirus 
against a lethal influenza challenge in intranasally immu-
nized mice (Abe et al., 2003). A complement regulatory 
protein in the BV envelope has been shown to protect the 
baculovirus gene therapy vector against complement 
mediated inactivation (Hüser et al., 2001). This type of 
strategy can be applied for vaccine production.  
It has been reported that the baculovirus insect cell 
production technology could be used for rapid vaccine 
production and this technique is especially suitable for 
influenza vaccines (Cox, 2008; Safdar and Cox, 2007). 
 
 
Combinations of vaccine strategies 
 
The efficiency of combining different vaccine strategies is 
currently being explored to improve on the adjuvant 
therapy of melanoma (Kirkwood et al., 2006; Gogas et al., 
2006). Recently, it has been found that in tuberculosis 
and HIV infection, the accent is currently being placed on 
the use of antimalarial combinations in order to overcome 
the problem of multidrug resistance which are particularly 
good candidates for combination therapy (Olliaro and 
Taylor, 2004). 
It has been recently studied that in cancer treatment, 
there is the combination of vaccination with other thera-
pies (Andersen et al., 2008; Colombo and Piconese, 
2007). Vaccine development for humans against 
diseases is basically carried out using cattles as a model. 
It has been reported that prime boost vaccination strate-
gies using (bovis bacillus Calmette-Guérin) combinations 
of BCG and DNA vaccines could provide better protection 
than either vaccine alone (Dle et al., 2005). 
 
 
Viral marker vaccines and differential diagnosis 
technology 
 
Improving the vaccine purity, potency, safety and efficacy 
is of paramount importance before the actual field trials. 
This technology makes it possible to retain the 
advantages, while overcoming the safety hazards and 
logistical disadvantages, inherent in many modified live 




Subunit vaccines  
 
These are used for marker vaccines development. Peptide 
Peptide vaccines are one form of subunit vaccine that is 







Organisms with their virulence gene deleted can be used 
as live attenuated vaccines. Such genetically engineered 
vaccines are less likely to be a safety risk. Besides, gene 
deleted vaccine organism may also serve as an excellent 
vector for genes of other pathogens (Kimman, 1992). 
 
 
Live vectored vaccines  
 
Live recombinant vector strains express one or more 
protective genes from another microorganism. The 
advantage is that they may be effective in overcoming the 
interference with the maternal antibody immune response 
(Monteil et al., 2000). The use of viral vectors for 
development of veterinary vaccines has been reviewed 





It consists of bacterial plasmids which are purified and 
injected into host animal cells that express the targeted 
antigen. Immune responses induced by DNA vaccines 
can be more variable than those by more conventional 
technologies; these must be assessed and balanced with 
the advantages of a particular DNA vaccine (Roth and 





Plants, plant cell cultures and plant viruses have been 
developed to produce antigens or antibodies for 
vaccines, therapeutics and diagnostic tests (Wigdorovitz 
et al., 1996). 
 
 




Conventional diagnostic assays have relied on detection 
of the agent using a variety of techniques such as virus 




Western blot technologies 
 
There has been an increasing use of Western blot assays 
for highly specific confirmatory tests to more accurately 
identify cross-reactions, resulting in finding unexpected 
positive reactions from animals that come from popu-




Nucleic acid technologies 
 
The development and optimization of nucleic acid amplifi- 




cation and detection techniques have resulted in the 
ability to quickly detect and identify a number of agents 
directly from host animal samples without waiting for 
culture results (Roth and Henderson, 2001). This 
technique has been used to detect a number of agents of 
veterinary interest including West Nile virus (Wigdorovitz 





Biosensors involve the use of a receptor (usually an 
antibody) for the target pathogen or a disease-specific 
antibody and a transducer which converts a biological 
interaction into a measurable signal (David et al., 2008). 
Thus, in future, a number of technological 
developments will hold tremendous potential for creative 








Immunogenicity testing of Plasmodium falciparum 
antigens, considered as a suitable candidate for 
development of malaria vaccines, was undertaken in 
rabbits. Also, there is a report on the comparative testing 
of six P. falciparum merozoite stage antigen-based 
malaria vaccine.  
Baculovirus MSP-119
 immunizations produced the 
highest parasite-specific antibody titers in IFA (immuno-
fluorescence assays). Antibodies induced by baculovirus 
MSP-119 gave the highest levels of growth inhibition in 
HB3 and 3D7 parasite cultures, followed by AMA-1+MSP-
119 and the
 AMA-1/MSP-119 fusion. Comparative
 analysis 
of immunogenicity of vaccine antigens can be used to 
prioritize  candidates  before  moving  to  expensive GMP 
production and clinical testing. 
An experiment conducted using Baculovirus-Expressed 
Constructs on rabbit  revealed  that  on  expression;  they 
induce Immunoglobulin G (IgG) that recognizes VAR2CS 
A antigen on P. falciparum- infected erythrocytes. The 
end result thus, indicated that most domains of native 
VAR2CSA on the surface of intact infected erythrocytes 
are accessible to IgG and thus constitute a potential 





Babesia rodhaini antigen p26 was expressed in 
Escherichia coli and when it was introduced into infected 
insect cells along with a recombinant baculovirus, good 
effective results were found (Igarashi et al., 2000). 
 
 
CONCLUSION AND RECOMENDATION 
 
The past over view shows that animal vaccine development 




has advanced with the availability of new knowledge and 
methodology in molecular biology and biotechnology. 
Glycoproteins which are suitably expressed in the 
BEVS are good candidate sources for vaccine 
development. The combination of subunit vaccines and 
marker tests, both based on antigens expressed in insect 
cells, provides a powerful tool to combat disease and to 
monitor infectious agents. Apart from that it can be said 
that animal vaccine might be produced in baculovirus 
insect cell expression system. And our hypothesis is that 
baculovirus insect cell expression system tool will be a 
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